Vivakor Presents at Nutraceutical Event
November 12 2009 - 4:36PM
PR Newswire (US)
CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ -- Vivakor, Inc.
(OTC Bulletin Board: VIVK) is the keynote presenting company at the
founders' celebration of consumer product specialist, Regeneca
International, Inc. (http://www.regeneca.com/). The celebration
will be attended by over 200 founders and guests of Regeneca
International from across the United States. It will be hosted at
the prestigious Balboa Bay Club in Newport Beach, California.
Vivakor's Chairman, Matt Nicosia and CFO, Ed Corrente will both be
attending the event. Event attendee, Dr. Brian Scott , a Regeneca
advisory board member and nationally recognized wellness expert,
was particularly pleased to learn of Vivakor's role in the event.
"As a healthcare provider and speaker on issues regarding wellness
and longevity, it is refreshing to hear the perspective of a
company, doing business internationally, which can provide a
particular focus on products which extend the length and quality of
a person's life." The purpose of the event is to introduce
Regeneca's new product offerings that are to be released in the
coming months, most significantly, the new nutraceutical
formulation developed by Vivakor." About Vivakor, Inc. Vivakor,
Inc. is a transdisciplinary research company that develops and
acquires products in the fields of molecular medicine,
electro-optics, biological handling and natural and formulary
compounds. Vivakor also provides contract research services for
third parties. Vivakor's business model is to be a research hub
focused on areas that have both an identified scientific need and a
substantial market opportunity with a significant market. This
approach is intended to provide the necessary environment of
transdisciplinary collaboration and cross-pollination to advance
research and technology acquisition. Vivakor's mission is to
advance or acquire distinct intellectual property and technologies
that improve the quality of life for individual patients,
researchers, clinicians and consumers. Vivakor believes that the
development and commercialization of substantive technologies and
cures for complex human conditions, illnesses and diseases require
a sophisticated approach with contribution from many areas of
business and scientific expertise. Vivakor's research and the
technology it acquires are anchored by its relationship with
collaborative partners and product-specific commercialization
strategies. From the commencement of product conception or
acquisition, through development and commercialization, the Company
expects to have collaborative partners or licensing arrangements in
place for each of its products. Vivakor expects this model to
provide several advantages, including: (i) a more efficient
research and development process; (ii) a quicker time to market
after completion of development; and (iii) the value-add growth to
the hub company, Vivakor, through commercialization and subsidiary
spin-off. Vivakor has commenced developing numerous products and
currently has one pending utility patent. In October, 2008, it
acquired a patented MRI software technology that it intends to
develop. Vivakor generally intends to commercialize its products,
after completion of development and any required regulatory
approvals, primarily through one of three methods: (i) a sale of
the technology; (ii) licensing of the product to a manufacturer or
distributor or; (iii) by directly manufacturing, marketing and
selling the products. Product Research Divisions Vivakor's research
efforts are divided into four primary areas of medical and
biotechnological development. These are: 1. Molecular Medicine. The
goal of this division centers on the development of biologically
relevant molecules, tests and methods and their application in the
practice of medicine. Vivakor plans to translate systems biology
(genomics, proteomics, metabalomics, etc.) insights of the
molecular and cellular basis of disease into commercializable
theranostic (diagnostic/therapeutic) products. Vivakor scientists
will be participants in the discovery and development of new drugs
and the early diagnosis of disease states. The central aim of the
molecular medicine division is cancer detection and wound healing,
which we anticipate will lead to the development of customized
treatments. Research in stem cell biology and nuclear reprogramming
is a critical element in this research. 2. Electro-Optics. This
division is charged with the development of biomedical and related
consumer products that incorporate optical and electronic
engineering. Vivakor has actively designed, built and tested
several new electro-optic devices to reach previously un-served or
underserved areas of the biomedical device market and believes the
market potential during the first 12 months of commercialization of
these products is over $15 million. Products scheduled for
development in this area include: -- VivaSight: a digital
photorefractor that is intended to modernize child vision
screening. Approval has been granted from Western Institutional
Review Board (20080731) to conduct human validation studies of the
VivaSight technology on children. This study is currently being
conducted at The University of Iowa Hospitals and Clinics. --
Clinical Biomolecular Sensor (CBS): a label free multiplexed
approach for use in the detection and diagnosis of complex human
conditions (cancer, infectious diseases, cardiovascular disease,
metabolic disorders, auto immune and inflammatory
diseases)Multi-spectral Imaging: devices to examine burn degree and
cutaneous melanoma and -- Spectroscopic devices: to track wound
healing and ear infection. With the acquisition of HealthAmerica's
SLICES(TM) technology, the Company plans to adapt and upgrade this
technology to produce enhanced MRI images, which are expected to
improve MRI resolution while providing additional data such as
blood flow velocity in imaged tissues. The Company believes its
potential market share for this product is over $300 million
annually . 3. Biological Handling. Vivakor has developed commercial
products for cryogengenic preservation, and storage through its
VivaThermic Cryovials (USPTO Utility Patent # 12423998) which are
currently being sold and have improved temperature control and were
designed to improve cryopreservation and thawing of sensitive
biological material. Vivakor expects that the market potential for
its products is over $10 million over the next 12 months. It plans
to continue to explore new techniques to improve methods and
products employed for cryogenic preservation, storage and handling.
Future research plans for this division include: -- stem cell
specific improved cryovials; -- cryogenic devices for temperature
maintenance and sample transport); -- a cryogenic biopsy device
(Cryopsy); and -- improved modular cryogenic freezer designs. 4.
Natural and Formulary Products. This division plans to focus on the
investigation, validation and adaptation of medical herbalism or
botanical medicine. The Company has already developed a series of
nutraceutical formulations, including VivaBlend, and plan to
develop additional nutraceuticals, botanicals and supplements.
Vivakor recently received a 25,000 unit purchase order for one of
our products from Regeneca, International. Future products for this
division include: -- fruit and vegetable extract for the protection
of digestive system -- fresh fruit and vegetable extract for
antioxidant supplements; and -- jam and jelly formula to contain
both antioxidant supplements as well as bone & cartilage
supplements for healthy joints More information can be found about
Vivakor at http://www.vivakor.com/. About Regeneca International,
Inc. Regeneca(TM) International, Inc. was formed to create and
commercialize products that help consumers improve their health,
battle the signs and symptoms of aging and to assist you
"regenerate their life" through its family of natural, organic and
phytochemical infused products. The corporate creed is to
regenerate the human genetic environment through ecology centric
science. All REGENECA(TM) products must fit the highest standard of
conservation, and reduced carbon footprint. The products must also
work to preserve and promote the user's health at the most
elemental level of life; the genetic level. The Company's products
and philosophy are designed to reconnect the consumer to the
Earth's source of healing properties, but with a symbiotic
approach. This is the Company's "Whole Earth, Whole Body Approach
to Health." Already a market presence in the multibillion dollar
nutraceutical market, Regeneca's proprietary, direct to consumer;
marketing strategy has pushed the company to the forefront of
emerging consumer product companies. Regeneca anticipates at least
a 500% increase in sales in 2010 and a similar increase in 2011.
More information can be found about Regeneca International, Inc. at
http://www.regeneca.com/ . FORWARD-LOOKING STATEMENTS This press
release may contain forward-looking statements, including, but not
limited to, statements regarding Vivakor's products and divisions
and their related market potential. There may also be similar
statements regarding Regeneca and its product divisions.
Forward-looking statements may be identified by the use of the
words "anticipates," "expects," "intends," "plans," "should,"
"could," "would," "may," "will," "believes," "estimates,"
"potential," or "continue" and variations or similar expressions.
These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks
and uncertainties include, but are not limited to, risks and
uncertainties discussed in Vivakor's filings with the Securities
and Exchange Commission, which factors are incorporated herein by
reference. Readers are cautioned not to place undue reliance on any
of these forward-looking statements. Vivakor undertakes no
obligation to update any of these forward-looking statements to
reflect events or circumstances after the date of this press
release or to reflect actual outcomes. Contact: Vivakor, Inc. Matt
Nicosia, 319-625-2172 DATASOURCE: Vivakor, Inc. CONTACT: Matt
Nicosia, Vivakor, Inc., +1-319-625-2172, Web Site:
http://www.vivakor.com/
Copyright